albendazole + ivermectin + azithromycin

This is a combination of three medications used in mass drug administration (MDA) programs for neglected tropical diseases (NTDs). The combination targets multiple parasitic and bacterial infections simultaneously. Pharmacokinetic studies have shown minimal clinically significant drug-drug interactions between these three medications when administered together. When combined, ivermectin levels (AUC and Cmax) increase by approximately 31% and 27% respectively, azithromycin levels increase by approximately 13% and 20%, while albendazole levels show minimal changes. These alterations in drug levels are considered small and within established safety ranges. The combination has been studied in field trials in Ethiopia and Mali, demonstrating non-inferior safety compared to separate administration.

Other names

triple co-administration of albendazole, ivermectin, and azithromycin